Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes which are members of the zinc endopeptidase family. They have the ability to degrade extracellular matrix elements, allowing for the release of binding molecules and cell migration. Although metalloproteinases regulate numerous physiological processes within the cornea, overexpression of metalloproteinase genes and an imbalance between the levels of metalloproteinases and their inhibitors can contribute to the inhibition of repair processes, the development of inflammation and excessive cellular proliferation. The involvement of MMPs in the pathogenesis of dystrophic corneal diseases needs clarification. Our analyses focus on the involvement of individual metalloproteinases in the pathogenesis of recurrent corneal erosions and highlight their impact on the development of corneal epithelial basement membrane dystrophy (EBMD). We hypothesize that abnormalities observed in patients with EBMD may result from the accumulation and activation of metalloproteinases in the basal layers of the corneal epithelium, leading to basement membrane degradation. A barrier formed from degradation materials inhibits the normal migration of epithelial cells to the superficial layers, which contributes to the development of the aforementioned lesions. This hypothesis seems to be lent support by the elevated concentrations of metalloproteinases in the corneal epithelium of these patients found in our previous studies on the relationships between MMPs and recurrent corneal erosions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525265PMC
http://dx.doi.org/10.3390/biology12091263DOI Listing

Publication Analysis

Top Keywords

recurrent corneal
12
corneal erosions
12
basement membrane
12
matrix metalloproteinases
8
metalloproteinases pathogenesis
8
pathogenesis recurrent
8
epithelial basement
8
membrane dystrophy
8
corneal epithelium
8
corneal
7

Similar Publications

Background: Corneal squamous cell carcinoma (cSCC) is a rare neoplasm of dogs that can be treated with various modalities, principally by superficial keratectomy (SK) surgery. It is common to treat cSCC with multiple adjunctive therapies, but this may not always be practical for clinicians, clients, or patients.

Aim: This retrospective study describes the signalment of affected dogs, concurrent medical therapy, and success rate of surgical treatment of cSCC with SK surgery alone or in combination with adjunct therapy.

View Article and Find Full Text PDF

We report a case of sympathetic ophthalmia that developed in the fellow eye following therapeutic corneal transplantation and amniotic membrane transplantation for corneal perforation caused by corneal ulceration. A 62-year-old man presented with discharge, lacrimation, and decreased visual acuity in the left eye. He was diagnosed with a corneal ulcer and treated with antimicrobial agents, but corneal epithelial erosion persisted, leading to nontraumatic corneal perforation.

View Article and Find Full Text PDF

Acquired Ankyloblepharon Correction Using Ocular Surface and Tarsal Mucous Membrane Grafting in Cicatrizing Ocular Surface Diseases.

Ophthalmic Plast Reconstr Surg

January 2025

Hariram Motumal Nasta & Renu Hariram Nasta Ophthalmic Plastic Surgery Services.

Purpose: To report the long-term surgical outcomes of acquired ankyloblepharon correction using mucous membrane graft.

Methods: Five eyes of 4 patients (median age, 19 years) with acquired ankyloblepharon were managed using eyelid splitting and mucous membrane graft anchored to the recti muscles on the bulbar surface in the respective quadrant and onto the bare tarsal surface. Outcome measures include a change in the palpebral fissure width, ability to fit scleral contact lenses, visual acuity, and cosmesis.

View Article and Find Full Text PDF

We describe a novel technique for recurrent pterygium and assess the advantage of properties of extended tenonectomy, amniotic membrane transplantation, and limbal epithelial transplantation in terms of recurrence rate, postoperative symptoms, postoperative orthoptics, and other complications. A total of nine eyes with recurrent pterygium underwent PERMISLET, i.e.

View Article and Find Full Text PDF

Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.

Sci Rep

December 2024

Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, RM305v, 1160 W. Michigan St., Indianapolis, IN, 46202, USA.

Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently, surgical removal is the only effective treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!